Market Overview - The ChiNext Index fell by 0.19%, closing at 2039.45 points, with a total trading volume of 298.46 billion yuan, a decrease of 17.36 billion yuan compared to the previous trading day [1] - Among the tradable ChiNext stocks, 854 stocks closed higher, with 19 stocks rising over 10%, including Greebo, Tuoxin Pharmaceutical, and Haoen Automotive, which hit the daily limit [1] Trading Activity - The average turnover rate for the ChiNext today was 3.16%, with 44 stocks having a turnover rate exceeding 20% [1] - C Zerun, a newly listed stock, had the highest turnover rate at 79.01%, closing up by 99.52% with a trading volume of 813 million yuan [1][2] - Other high turnover stocks included Zhongzhou Special Materials and Hengxin Life, with turnover rates of 41.61% and 40.19%, respectively [1][2] Institutional Activity - Eight high turnover ChiNext stocks appeared on the Dragon and Tiger List, with seven stocks showing institutional participation [3] - New Han New Materials had four institutional seats with a total net purchase of 39.83 million yuan, while Tianyuan Pet had four institutional seats with a net purchase of 31.30 million yuan [3] Fund Flow - Among high turnover stocks, 27 stocks saw net inflows from main funds, with the highest inflows in Yian Technology, Zhongzhou Special Materials, and C Zerun, amounting to 384 million yuan, 354 million yuan, and 167 million yuan, respectively [3] - Conversely, stocks like Chuaning Biological and Tuoxin Pharmaceutical experienced significant net outflows, with amounts of 534 million yuan and 17 million yuan, respectively [3] Performance Summary - Two high turnover stocks released half-year performance forecasts, with one stock expecting a profit increase [4] - Zhongjie Automotive is projected to have a net profit median of 48 million yuan, representing a year-on-year increase of 4.72% [4]

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

拓新药业集团股份有限公司 关于子公司变更食品生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）全资子公司新乡精泉生物 技术有限公司（以下简称"精泉生物"）于近日收到河南省市场监督管理局颁发 的《食品生产许可证》，同意公司《食品生产许可证》的变更申请，本次变更主 要涉及新增 5 个产品的生产，现将有关情况公告如下： 一、新取得的《食品生产许可证》具体信息 1.生产者名称：新乡精泉生物技术有限公司 2.法定代表人（负责人）：刘德前 证券代码：301089 证券简称：拓新药业 公告编号：2025-025 三、对公司的战略价值 1 3.住所：河南省新乡市高新区静泉东路 266 号 4.生产地址：河南省新乡市高新区静泉东路 266 号 5.食品类别：其他食品；食品添加剂 6.许可证编号：SC20141070100403 7.统一社会信用代码:91410700MA9L9KWMXJ 8.发证机关：河南省市场监督管理局 9.有效日期至：2029 年 04 月 11 日 二、新增生产许可产品清单 本次变更新增食品添加 ...

Core Viewpoint - Synthetic biology concept stocks are experiencing significant upward movement, with notable gains in several companies [1] Group 1: Company Performance - Chuaning Biological (301301) reached a 20% daily limit increase [1] - Bawi Co., Ltd. saw an increase of over 20% [1] - Toxin Pharmaceutical (301089) rose by more than 10% [1] - Jindawei (002626), Oukang Pharmaceutical, and Weilan Biological (603739) also experienced upward trends [1] Group 2: Market Activity - There is a notable influx of dark pool funds into these stocks [1]

Group 1: Company Overview and Financial Performance - As of May 9, 2025, the number of shareholders is 16,802 [2] - In 2024, the company's net cash flow from operating activities was ¥102,668,700.92, a year-on-year increase of 280.91% [4] - The company's revenue for 2024 was ¥421,694,066.41 [7] Group 2: Product Development and Market Strategy - In 2024, the company established a full subsidiary in Hainan to leverage geographical and policy advantages for overseas market expansion [2] - The company received food production licenses for various products, including d-ribose and 5'-uridine monophosphate disodium, enhancing its product offerings [3] - The company is actively developing health-related products, including nutritional enhancers and food additives, with successful large-scale production of some functional foods [5] Group 3: Research and Development - In 2024, R&D expenses were ¥40,046,804.25, a decrease of 21.86% from the previous year [6] - The company has made significant progress in drug registration, with two raw material drug applications accepted and one approved for market [6] - The company is focusing on expanding its product pipeline in the health sector, including dietary supplements and functional foods [11] Group 4: Environmental and Social Responsibility - In 2024, the company invested approximately ¥11.56 million in environmental protection, achieving significant results in equipment upgrades and resource recycling [10] - The company maintains a stable profit distribution policy, emphasizing reasonable returns to investors while ensuring sustainable development [7] Group 5: Market Challenges and Future Outlook - The company faced a significant revenue decline in 2024, primarily due to a drop in sales of COVID-19 related drugs [10] - The company plans to optimize management processes and reduce costs to improve operational efficiency [10] - Future growth strategies include expanding into the health industry and enhancing product offerings through technological innovation [11]

欢迎广大投资者积极参与本次网上业绩说明会。 （问题征集专题页面二维码） 证券代码：301089 证券简称：拓新药业 公告编号：2025-024 拓新药业集团股份有限公司 关于举行2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）定于2025年5月14日（周 三）下午15:00-17:00在全景网举办2024年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事、总经理杨邵华先生，财务总监焦慧 娟女士，董事会秘书杨钰华女士，独立董事刘建伟先生，保荐代表人郑俊杰先 生。 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2025年5 月13日（周二）下午17:00前访问全景网（http://ir.p5w.net/zj/）或扫描下 方二维码，进入问题征集专题页面。敬 ...

各位股东及股东代表： 拓新药业集团股份有限公司独立董事2024年度述职报告 拓新药业集团股份有限公司 独立董事2024年度述职报告 作为拓新药业集团股份有限公司（以下简称"公司"）第四届董事会的独 立董事，本人严格按照《公司法》《深圳证券交易所创业板股票上市规则》等 法律法规和《公司章程》《独立董事工作制度》等内部控制文件的规定，在 2024年的工作中，勤勉、忠实、尽职的履行职责，充分发挥独立董事作用，维 护公司整体利益和全体股东尤其是中小股东的合法权益，现就本人2024年度履 职情况报告如下： 一、出席会议情况 2024年度，本着勤勉尽责的态度，本人积极参加公司召开的股东大会、董 事会，认真审阅会议材料，积极参与各议题的讨论并提出合理建议，以谨慎的 态度行使表决权，为股东大会、董事会的正确决策发挥了积极的作用。 本人出席了公司2024年度召开的2次股东大会，出席会议情况如下： | 本年应参加股东大会次数 | 亲自出席次数 | 委托出席次数 | 缺席次数 | | --- | --- | --- | --- | | 2 | 2 | 0 | 0 | 本人出席了公司2024年度召开的4次董事会，各项议案均投赞成票， ...

各位股东及股东代表： 作为拓新药业集团股份有限公司（以下简称"公司"）第五届董事会的独 立董事，本人严格按照《公司法》《深圳证券交易所创业板股票上市规则》等 法律法规和《公司章程》《独立董事工作制度》等内部控制文件的规定，在 2024年的工作中，勤勉、忠实、尽职的履行职责，充分发挥独立董事作用，维 护公司整体利益和全体股东尤其是中小股东的合法权益，现就本人2024年度履 职情况报告如下： 拓新药业集团股份有限公司独立董事2024年度述职报告 拓新药业集团股份有限公司 独立董事2024年度述职报告 一、出席会议情况 2024年度，本着勤勉尽责的态度，本人积极参加公司召开的股东大会、董 事会，认真审阅会议材料，积极参与各议题的讨论并提出合理建议，以谨慎的 态度行使表决权，为股东大会、董事会的正确决策发挥了积极的作用。 本人出席了公司2024年度召开的2次股东大会，出席会议情况如下： | 本年应参加股东大会次数 | 亲自出席次数 | 委托出席次数 | 缺席次数 | | --- | --- | --- | --- | | 2 | 2 | 0 | 0 | 本人出席了公司2024年度召开的4次董事会，各项议案均投赞成票， ...

拓新药业集团股份有限公司独立董事2024年度述职报告 拓新药业集团股份有限公司 独立董事2024年度述职报告 各位股东及股东代表： 作为拓新药业集团股份有限公司（以下简称"公司"）第五届董事会的独 立董事，本人严格按照《公司法》《深圳证券交易所创业板股票上市规则》等 法律法规和《公司章程》《独立董事工作制度》等内部控制文件的规定，在 2024年的工作中，勤勉、忠实、尽职的履行职责，充分发挥独立董事作用，维 护公司整体利益和全体股东尤其是中小股东的合法权益，现就本人2024年度履 职情况报告如下： 一、出席会议情况 2024年度，本着勤勉尽责的态度，本人积极参加公司召开的股东大会、董 事会，认真审阅会议材料，积极参与各议题的讨论并提出合理建议，以谨慎的 态度行使表决权，为股东大会、董事会的正确决策发挥了积极的作用。 本人出席了公司2024年度召开的2次股东大会，出席会议情况如下： | 本年应参加股东大会次数 | 亲自出席次数 | 委托出席次数 | 缺席次数 | | --- | --- | --- | --- | | 2 | 2 | 0 | 0 | 本人出席了公司2024年度召开的4次董事会，各项议案均投赞成票， ...

拓新药业集团股份有限公司 关于2024年年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 根据中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》 和深圳证券交易所颁布的《深圳证券交易所创业板股票上市规则（2024年修订）》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 （2023 年 12 月修订）》等有关规定，现将拓新药业集团股份有限公司（以下简 称"公司"）2024 年年度募集资金存放与使用情况专项报告如下： 一、募集资金基本情况 1、实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可［2021］3021 号文核准，公司于 2021 年 10 月 27 日向社会公开发行人民币普通股（A 股）31,500,000 股，每股发行价 为 19.11 元，募集资金总额为人民币 601,965,000.00 元，根据有关规定扣除发行 费用 58,690,890.23 元后，实际募集资金金额为 ...